Positive diabetes drug data revealed

Global pharmaceutical company Novo Nordisk has reportedly released positive new diabetes clinical trial data. The results, published in the Lancet, concern the diabetes drug liraglutide.
The new data reported shows that when liraglutide is taken alone it significantly improves and maintains improvements in blood glucose control amongst type 2 diabetes patients.
Liraglutide was also found to be associated with weight loss, lower blood pressure, and lower hypoglycaemia following a year of treatment. The principal study investigator, Alan Garber, reportedly commented:
“Publication of this data in the Lancet means that more physicians will have access to these key results on liraglutide’s efficacy as monotherapy in the treatment of type two diabetes .”